Cannabinoids in glaucoma: a primary screening procedure.
A procedure was developed for screening of cannabinoids for their ability to reduce intraocular pressure (IOP) using normal rabbits. Eight animals per group were used for statistical significance of data. A negative control group was used for every screen as well as a positive control with 1.5 mg/kg delta 9-THC given intravenously (I.V.). All compounds were tested by I.V. injection and IOP measurements were taken periodically for 5 hours. Data were analyzed by a computer program which takes into account the change in IOP of the control group. Following this procedure we found that delta 8-THC, delta 9-THC, cannabinol, and nabilone were active while cannabidiol was inactive.
D000818:Animals; D002185:Cannabidiol / Q000627:therapeutic use; D002186:Cannabinoids / Q000627:therapeutic use*; D002187:Cannabinol / Q000627:therapeutic use; D013759:Dronabinol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D011817:Rabbits
D002186:Cannabinoids; D002185:Cannabidiol; C011941:nabilone; D013759:Dronabinol; D002187:Cannabinol